BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15982605)

  • 1. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
    White M; Ross H; Haddad H; LeBlanc MH; Racine N; Pflugfelder P; Giannetti N; Davies R; Azevedo E; Isaac D; Burton J; Ferguson R; Genest J
    Transplantation; 2006 Sep; 82(6):763-70. PubMed ID: 17006323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
    Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
    Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
    Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
    Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
    Gelens MA; Christiaans MH; v Hooff JP
    Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
    Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
    Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
    Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
    Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant.
    Roy A; Kneteman N; Lilly L; Marotta P; Peltekian K; Scudamore C; Tchervenkov J
    Transplantation; 2006 Aug; 82(4):494-500. PubMed ID: 16926593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
    Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
    J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
    Neal DA; Gimson AE; Gibbs P; Alexander GJ
    Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis.
    Ye F; Ying-Bin X; Yu-Guo W; Hetzer R
    J Heart Lung Transplant; 2009 Jan; 28(1):58-66. PubMed ID: 19134532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation.
    Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS
    Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
    Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
    J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.